Make Healthcare Accessible & Affordable to Patients Globally

During the last three years Dyadic (Dyadic International, Inc.; NASDAQ: DYAI) and VTT have developed a more efficient and lower cost alternative to produce therapeutic proteins, vaccines and valuable metabolites. The method is based on exploiting the Thermothelomyces heterothallica C1 fungal strain. The partners are now developing a new production method for a SARS-CoV-2 coronavirus vaccine.